Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Bleeding patterns during continuous combined estrogen-progestogen therapy.

U Marslew1, B J Riis, C Christiansen

  • 1Department of Clinical Chemistry, Glostrup Hospital, University of Copenhagen, Denmark.

American Journal of Obstetrics and Gynecology
|May 1, 1991
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bone mineral density response rates are greater in patients treated with abaloparatide compared with those treated with placebo or teriparatide: Results from the ACTIVE phase 3 trial.

Bone·2018
Same author

Cohort Profile: The Prospective Epidemiological Risk Factor (PERF) study.

International journal of epidemiology·2016
Same author

Treatment of symptomatic knee osteoarthritis with oral salmon calcitonin: results from two phase 3 trials.

Osteoarthritis and cartilage·2015
Same author

OA phenotypes, rather than disease stage, drive structural progression--identification of structural progressors from 2 phase III randomized clinical studies with symptomatic knee OA.

Osteoarthritis and cartilage·2015
Same author

Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.

Bone·2012
Same author

Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2011

Continuous estrogen and progestogen therapy effectively manages menopausal symptoms like hot flashes. However, different progestogens vary in their ability to control bleeding patterns and induce amenorrhea.

Area of Science:

  • Reproductive Endocrinology
  • Menopause Management
  • Hormone Replacement Therapy

Background:

  • Postmenopausal women often experience climacteric symptoms and bleeding irregularities.
  • Continuous combined hormone therapy aims to alleviate symptoms while managing bleeding.

Purpose of the Study:

  • To compare the efficacy of two continuous combined hormone replacement therapy regimens in managing menopausal symptoms and bleeding patterns.
  • To assess the impact of different progestogens on bleeding control and amenorrhea in postmenopausal women.

Main Methods:

  • A 2-year, double-blind, placebo-controlled study involving 99 postmenopausal women aged 45-54 years.
  • Two treatment groups received either estradiol and norethisterone acetate or estradiol and cyproterone acetate.

Related Experiment Videos

  • Bleeding patterns, climacteric symptoms (Kupperman index, hot flushes) were recorded.

    • Main Results:

    • A statistically significant difference in bleeding patterns was observed between the groups.
    • The estradiol-cyproterone acetate group experienced more frequent and longer bleeding episodes.
    • Amenorrhea rates were higher in the estradiol-norethisterone acetate group (13 women vs. 2 women).
    • Both groups showed significant reductions in Kupperman index scores and hot flushes (p < 0.001).

    Conclusions:

    • Continuous combined estrogen and progestogen therapy provides symptomatic relief and can induce amenorrhea.
    • The choice of progestogen component significantly influences bleeding control in hormone replacement therapy.